SCHEMBL6235955

SCHEMBL6235955

O=c1c(C2=NS(=O)(=O)c3ccccc3N2)c(O)c2ccccc2n1Cc1cccc([N+](=O)[O-])c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.61
HSD17B10 Q99714 1/20 0.61
NR1I2 O75469 1/20 0.50
CYP2C9 P11712 1/20 0.50
KMT2A Q03164 5/20 0.48
NOX4 Q9NPH5 1/20 0.47
MEN1 O00255 3/20 0.46
FEN1 P39748 1/20 0.42
ALDH1A1 P00352 4/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
CA12 O43570 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
RECQL P46063 1/20 0.41
CASP6 P55212 1/20 0.41
CFTR P13569 4/20 0.41
HPGD P15428 2/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6233469 0.91 MAPK1 (0.64) MAPK1HSD17B10NR1I2CYP2C9KMT2A
SCHEMBL1522232 0.89 MAPK1 (0.49) MAPK1HSD17B10NR1I2CYP2C9KMT2A
SCHEMBL6235315 0.86 MAPK1 (0.65) MAPK1HSD17B10NR1I2CYP2C9KMT2A
SCHEMBL6739063 0.83 MAPK1 (0.64) MAPK1HSD17B10NR1I2CYP2C9KMT2A
SCHEMBL6233389 0.82 MAPK1 (0.69) MAPK1HSD17B10NR1I2CYP2C9KMT2A
SCHEMBL6738199 0.81 MAPK1 (0.66) MAPK1HSD17B10NR1I2CYP2C9KMT2A
SCHEMBL6733839 0.81 MAPK1 (0.68) MAPK1HSD17B10NR1I2CYP2C9KMT2A
SCHEMBL6738676 0.81 MAPK1 (0.66) MAPK1HSD17B10NR1I2CYP2C9KMT2A
SCHEMBL6234470 0.81 MAPK1 (0.63) MAPK1HSD17B10NR1I2CYP2C9KMT2A
SCHEMBL6237190 0.81 MAPK1 (0.67) MAPK1HSD17B10NR1I2CYP2C9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US claimed
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP disclosed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US disclosed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP disclosed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 MAPK1 3699/4885HSD17B10 1428/4885NR1I2 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.